17,261 trials
Haemostasis · Haemophilia A
Primary: The Number of Bleeding Episodes During at Least 24 Weeks From Treatment Onset — 43; 13; 14 Episodes
Pelvic Adhesions
Primary: Number of Participants in Which Adhesions Were Prevented. — 15; 5; 4; 3 Participants
Follicular Lymphoma · Marginal Zone B-Cell Lymphoma · MALT Lymphoma
Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) — 260; 472; 2210; 4160 h*pg/mL
Metastatic Malignant Neoplasm in the Lung · Metastatic Osteosarcoma · Recurrent Osteosarcoma
Primary: Disease Control — 11 Participants
AL Amyloidosis
Primary: Assess the Number of Patients Who Respond to Treatment — 5; 13; 2; 1 Participants
Colon Cancer With Metastases to the Liver
Primary: Tumor Response — 31; 16 participants
Dementia, Alzheimer Type
Primary: ADAS-Cog v14 — -1.5; -0.7 units on a scale
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS), Groups A-D Only — 15.0; 6.7; 6.0; 5.9 Months — p=0.5050
Macular Degeneration
Primary: Time Until a Participant First Requires the Implant Refill According to Protocol-Defined Refill Criteria — 8.7; 13.0; 15.8 Months
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Evaluable Patients Alive at 6 Months — 71 percentage of participants
Breast Cancer
Primary: Participants With Dose Limiting Toxicities by Preferred Term in Cycle 1 (28 Days) - in Phase I — 1; 1; 0; 0 Participants
Inflammatory Lung Injury · Ischemia-Reperfusion Lung Injury · Postoperative Pulmonary Complications
Primary: Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha (pg/mL) — 0.53; 0.53; 22.06; 102.04 pg/mL
Recurrent Follicular Lymphoma · Recurrent Mantle Cell Lymphoma · Recurrent Marginal Zone Lymphoma
Primary: Phase I: The Maximum Tolerated Dose (MTD) of Temsirolimus in Combination With Bortezomib, Rituximab and Dexamethasone — NA; NA mg